Determinants of AIDS and non-AIDS related mortality among people living with HIV in Shiraz, southern Iran: a 20-year retrospective follow-up study

Zahra Gheibi1, Zahra Shayan2*, Hassan Joulaei3, Mohammad Fararouei4, Shohreh Beheshti5 and Mostafa Shokoohi6,7

Abstract

Background: Human Immunodeficiency Virus (HIV) infection has become a global concern. Determining the factors leading to death among HIV patients helps controlling Acquired Immune Deficiency Syndrome (AIDS) epidemic. Up to now, little is known about mortality and its determinants among people living with HIV in the Middle East and North Africa (MENA) region, including Iran. The purpose of this study was to assess the risk factors of AIDS-Related Mortality (ARM) and Non-AIDS-Related Mortality (NARM) among people with HIV in Iran.

Methods: This 20-year retrospective study was conducted on 1160 people with HIV whose data were collected from 1997 to 2017. The association of the study outcomes (ARM and NARM) with various study variables, including demographic status at the time of diagnosis and clinical indexes during the follow-up were examined to define the predictors of mortality among the patients. Regarding, Cox proportional hazard and competing risk models were fitted and Adjusted Hazard Ratios (AHR), Sub-distribution Hazard Ratio (SHR) and the 95% Confidence Intervals (CI) were reported.

Results: during the follow-up period, 391 individuals (33.7%) died with 86,375 person-years of follow-up. Of the total deaths, 251 (64.2%) and 140 (35.8%) were ARM and NARM, respectively. Rates of the mortality caused by AIDS and non-AIDS were 3.2 and 4.5 per 1000 person-months, respectively. Responding to combined Antiretroviral Treatment (cART) 6 months after initiation, receiving Pneumocystis Pneumonia (PCP) prophylaxis, and higher CD4 count at diagnosis, reduced the hazard of ARM and NARM. However, older age, late HIV diagnosis, and last HIV clinical stages increased the hazard of AIDS related to mortality. Additionally, male gender, older age, incarceration history, and last HIV clinical stages increased the non-AIDS mortality.

Conclusions: Mortality caused by AIDS and non-AIDS remains high among people with HIV in Iran, particularly among males and those with late diagnosis. It seems that applying effective strategies to identify infected individuals at earlier stage of the infection, and targeting individuals with higher risk of mortality can decrease the mortality rate among HIV infected people.

Keywords: HIV, AIDS, Risk factors, Death, Competing risk

* Correspondence: shayanz@sums.ac.ir
2Trauma Research Center, Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Human Immunodeficiency Virus (HIV) is still a major public health issue in all around the world. Since the beginning of the AIDS epidemic, approximately 78 million people have been infected by HIV, and 35 million people have died because of AIDS-related diseases [1]. In the recent years, access to Highly Active Anti-Retroviral Therapy (HAART) has dramatically changed the AIDS epidemic, along with the rate of AIDS-Related Deaths (ARMs) [2, 3]. Therefore, ART is expected to help People Living With HIV (PLWH) to have the similar life expectancy to the general population [4, 5]. However, this goal has not been achieved, yet [6–8]. It has been predicted that increase in access to HAART and longer survival time would lead to more variations in the death causes among PLWH [3, 9, 10]. This is due to that as the proportion of ARMs is reducing because of HAART, PLWH are increasingly experiencing Non-AIDS-Related Deaths (NARMs) [11, 12].

HIV is also a public health challenge in Iran. According to the latest estimates of the United Nations Program on HIV/AIDS (UNAIDS), a total of 61,000 people (95% CI = (34,000, 120,000)) are living with HIV in Iran until 2018 [13]. Out of these patients, 9764 died and 14, 656 of them entered the AIDS stage [14]. Based on the number of registered patients, Fars province has the second rank in the country with approximately 5000 registered HIV-infected patients. According to the UNAIDS report, 4000 (2500–6200) cases of ARM were recorded in Iran, and the rate of newly detected HIV-infected cases has increased about 21% until 2016. However, it appears that ARM events have reduced by 14% since 2010 [15]. This reduction might be attributed to the change in the treatment policy of the time of starting HAART for PLWH. In Iran, until 2018, HAART was to be started when CD4 count was reduced to < 500 cell/mm² (200–350 cell/mm² before 2015). However, since 2019, the treatment regimen has been changed and HAART must currently be started as soon as the individual is diagnosed with HIV infection regardless of the level of CD4 [16].

The importance of analysis of data on death among PLWH has been shown in several studies. The results of such studies could identify the strengths and weaknesses of health policies for treatment of HIV patients, to achieve a longer time of survival [17–19]. The 90–90–90 targets have been set to be reached by 2020. In this regard, 90% of all patients with HIV infection will know their disease statuses, and at least 90% of them will receive ART, and also 90% of them will suppress their viral loads with sustained treatment [20]. Clearly, defining the factors causing death among HIV patients can help move towards the targets [21].

Recent studies have indicated that the main causes of death among PLWH are co-infections, such as oncogenic viruses, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), tuberculosis, medication-related toxicities, and consumption of illegal or recreational drugs. Moreover, several cohort studies have demonstrated that HIV/AIDS-related conditions are the most frequent causes of death [2, 3]. However, the causes of mortality, including non-AIDS-related malignancies, cancers, liver and renal failures, cardiovascular diseases, and drug abuse are getting more diverse [10, 22, 23]. Despite the large number of studies conducted on the causes of death among PLWH, no efficient study has been performed in this field in Iran up to now. Therefore, new studies are required to determine the prognostic factors affecting the survival of PLWH in Iran.

In the present study, HIV patients’ survival was investigated among the patients who were registered in Shiraz HIV/AIDS Research Center during 1997–2017. With respect to the standard guidelines, the causes of death among HIV patients are classified to ARM and NARM [10, 11, 24]. To provide a valid method to simultaneously detect the risk factors of both types of events, a stepwise algorithm in the competing risks model was used [25].

Methods

Study setting

This follow-up study was conducted at Shiraz HIV/AIDS Research Center, a referral center for individuals living with HIV in Fars province, Iran. Nearly 5000 patients were diagnosed at this center and almost 1160 cases followed their ART line with complete medical files. Data were recorder from all patients at this referral center from August 1997 to May 2017 and were extracted to a checklist. The checklist was completed by trained staff in terms of the World Health Organization’s (WHO) recommendations (Fig. 1).

Data collection

The required data were extracted from the patients’ medical files by trained staff. The files included the patients’ socio-demographic and clinical data. Patients who had any special condition, such as pregnancy and the age under 16 years old, were excluded due to their very small numbers and special clinical conditions.

Coding the cause of death

The response variable was defined as the time interval from HIV detection to death. For The individuals who were alive by May 2017, the times of data extracting, were considered as “censored”. ARM and NARM were classified based on the coding causes of death in HIV (CoDe) protocol [10]. The CoDe protocol is a uniform coding method that was developed through Copenhagen HIV Program (CHIP) (Copenhagen University, Copenhagen, Denmark) to collect
data on the causes of death and its contributing factors. Deaths caused by AIDS or immunodeficiency conditions were classified as ARM. With respect to the CoDe protocol, ARM included three categories: opportunistic diseases, cancers such as cervical cancer, and other causes related to HIV/AIDS. On the other hand, NARM was defined as HIV-unrelated mortality, which included five categories: external causes (unexpected death like accident or overdose), hepatitis and liver-related deaths, Cardiovascular Diseases (CVD), cancers unrelated to HIV like lung cancer, and other causes. All deaths with unidentified causes were included in the analysis, if at least one CD4 was recorded in 6 months before the patient’s death. The individuals who died with CD4 counts < 200 cells/mm² were classified as ARM, while those who died with higher CD4 counts were considered as NARM. Categorization of the causes of death was accomplished based on the recorded underlying causes, and was independently performed by two qualified physicians specialized in HIV/AIDS care. In case of disagreement, a third expert was involved.

Variables
Two sets of covariates were considered. The first set of covariates was evaluated at diagnosis, which included age (continuous), gender (male, female), education level (less than secondary, secondary or above), marital status (married, unmarried, widowed/divorced), employment status (employed [i.e., reported having a job], unemployed), self-reported mode of HIV transmission (sexual, Injection Drug Use (IDU), etc.), and CD4 count (continuous). The other set of covariates was measured after diagnosis (i.e., in the follow-up period), which included drug abuse (none, drug used but being on Methadone Maintenance Therapy (MMT), drug use), linkage to HIV care defined as having visited centers providing HIV care and having access to ART and medical care after being diagnosed with HIV (yes, no), response to ART defined as indicating an improvement in clinical factors and/or increased CD4 counts by passing 6 months from ART initiation based on the medical records and physicians’ feedbacks (yes, no), late HIV diagnosis defined as less than 1 year between HIV diagnosis through an advanced phase of AIDS (yes, no), taking Pneumocystis Pneumonia (PCP) prophylaxis (yes, no), having HCV co-infection (yes, no), having HBV co-infection (yes, no), having tuberculosis co-infection (yes, no), and AIDS clinical stage defined based on WHO’s criteria (stages 1 and 2 vs. stages 3 and 4).

Statistical analysis
Descriptive statistics were reported as mean, Standard Deviation (SD), median, and interquartile range (Q1, Q3) for continuous measures, and as absolute and relative frequencies for categorical ones. In order to accomplish survival analysis, Cox model and competing risks analysis method were used to apply Hazard Ratio (HR) and Sub-distribution Hazard Ratio (SHR) for both groups of death events as they were proposed by Fine and Gray (1999) [26]. At First, an adjusted competing risk and Cox regression model was run for the first set of covariates (i.e., those obtained at diagnosis). Then, a second set of forward stepwise competing risk and Cox regression model was run for the covariates measured at the follow-up. Additionally, these covariates were adjusted for those measured covariates at diagnosis with p-values less than 0.20. All data analyses were carried out using Stata, version 14.

Results
In this study, a total of 1160 AIDS patients were enrolled due to the inclusion criteria. The mean age of the patients at diagnosis was 35.22 years old (SD = 8.43). Additionally, 1109 patients (95.6%) had not finished the compulsory education. Besides, the majority of them were male (n = 857, 73.9%). The transmission route was mainly injecting drugs in males (n = 719, 83.9%) and sexual contact in females (n = 262, 86.5%). All descriptive statistics of the study variables have been presented in Table 1. Totally, 391 patients (33.7%) died during the study period. Regarding, among these cases, 251 were considered as ARM (64.2%) and 140 of them were considered as NARM (35.8%). Opportunistic and AIDS-defining infections (n = 241, 96%) were accounted for the main causes of ARM. Among these cases with NARM, the most frequent cause of death was external causes (n = 78, 55.7%), including overdoses and driving accidents. Moreover, 14 deaths (7%) were related to cancer as shown in Table 2.

The results revealed different trends of mortality for different causes of death. The total rate of mortality increased with a starting rate as two deaths/100 person-years in 2006 and raised to 10 deaths/100 person-years in 2014. Afterwards, a remarkable fall was detected in 2016 (one death/100 person-years). As most causes of death were AIDS related, ARM had a similar trend to all-cause mortality. However, NARM remained fairly stable with a slight increase at the end of the study (from approximately one death/100 person-years to two deaths/100 person-years) (Fig. 2). Moreover, the cumulative incidence of ARM was more in comparison with that of NARM during the study (Fig. 3).

Based on the results of survival analysis on baseline characteristics, two variables; i.e., education level and employment status, had p-values more than 0.2. Therefore, they were excluded from all three multivariate models (Table 3). Moreover, mode of HIV transmission were not significant for the ARM model and CD4 count
| Baseline Characteristics | Entire cohort | AIDS-related mortality | Non-AIDS-related mortality | All-cause mortality |
|--------------------------|--------------|------------------------|----------------------------|-------------------|
| **Overall**              | 1160 (100)   | 251 (2.1)              | 140 (1.2)                 | 391 (3.3)         |
| **Gender**               |              |                        |                            |                   |
| Men                      | 857 (72.4)   | 215 (25.1)             | 136 (15.9)                | 351 (41.0)        |
| Women                    | 303 (26.1)   | 36 (11.9)              | 4 (1.3)                   | 40 (13.2)         |
| **Age**                  |              |                        |                            |                   |
| Median (Q1, Q3)          | 34 (29–40)   | 36 (30–43)             | 35 (30–41)                | 35 (30–42)        |
| < 30                     | 309 (26.6)   | 55 (17.8)              | 34 (11.0)                 | 89 (28.8)         |
| 30–39                    | 545 (47.0)   | 108 (19.8)             | 61 (11.2)                 | 169 (31.0)        |
| > =40                    | 306 (26.4)   | 88 (28.8)              | 45 (14.7)                 | 133 (43.5)        |
| **Marital status**       |              |                        |                            |                   |
| Married                  | 526 (45.3)   | 101 (19.2)             | 48 (9.1)                  | 149 (28.3)        |
| Single                   | 303 (26.2)   | 81 (26.7)              | 50 (16.5)                 | 131 (43.2)        |
| Widowed/divorced         | 331 (28.5)   | 69 (20.8)              | 42 (12.7)                 | 111 (34)          |
| **Education**            |              |                        |                            |                   |
| Less than secondary      | 403 (34.7)   | 93 (23.0)              | 50 (12.4)                 | 143 (35.5)        |
| Secondary or more        | 757 (65.3)   | 158 (20.8)             | 90 (11.8)                 | 237 (31.3)        |
| **Employment**           |              |                        |                            |                   |
| Employed                 | 549 (47.3)   | 112 (20.4)             | 77 (14.0)                 | 189 (34.4)        |
| Unemployed               | 611 (52.7)   | 139 (22.7)             | 63 (10.3)                 | 202 (33.1)        |
| **Incarceration history**|              |                        |                            |                   |
| No                       | 392 (33.8)   | 48 (12.2)              | 10 (2.6)                  | 58 (14.8)         |
| Yes                      | 768 (66.2)   | 203 (26.4)             | 130 (16.9)                | 333 (43.4)        |
| **Mode of HIV transmission** |         |                        |                            |                   |
| Sexual                   | 344 (29.7)   | 46 (13.4)              | 9 (2.6)                   | 55 (16.0)         |
| Injection drug use       | 733 (63.2)   | 185 (25.2)             | 123 (16.8)                | 308 (42.0)        |
| Othersa                  | 83 (7.1)     | 20 (24.1)              | 8 (9.6)                   | 28 (33.7)         |
| **CD4 count**            |              | 215 (102,352)          | 238 (127,254)             | 133 (63,260)      |
| Median (Q1, Q3)          |              | 215 (102,352)          | 238 (127,254)             | 133 (63,260)      |
| **Year HIV was diagnosed** |          |                        |                            |                   |
| Before 2011              | 712 (61.4)   | 46 (6.4)               | 35 (4.9)                  | 81 (11.3)         |
| 2011–2014                | 306 (26.4)   | 145 (47.3)             | 69 (22.5)                 | 214 (69.8)        |
| 2015–2017                | 142 (12.2)   | 60 (42.2)              | 36 (25.3)                 | 96 (67.5)         |
| **Covariates measured at follow-up** |       |                        |                            |                   |
| Drug use status          |              |                        |                            |                   |
| No drug use              | 307 (26.5)   | 36 (11.7)              | 5 (1.6)                   | 41 (16.0)         |
| On methadone therapy     | 568 (49.0)   | 101 (17.8)             | 65 (11.4)                 | 166 (42.0)        |
| Drug users               | 258 (24.5)   | 114 (44.2)             | 70 (27.1)                 | 184 (33.7)        |
| **Linkage to HIV care**  |              |                        |                            |                   |
| No                       | 219 (18.9)   | 124 (56.6)             | 72 (32.9)                 | 196 (89.5)        |
| Yes                      | 941 (81.1)   | 127 (13.5)             | 68 (7.2)                  | 195 (20.7)        |
| **Responded HAART 6 month after initiation** |       |                        |                            |                   |
| No                       | 392 (33.8)   | 239 (61)               | 97 (24.7)                 | 232 (59.2)        |
| Yes                      | 768 (66.2)   | 12 (1.6)               | 43 (5.6)                  | 159 (20.7)        |

Late HIV diagnosis
for the NARM model \( (p > 0.2) \) and consequently were removed.

The results of forward stepwise model proposed that “response to treatment” and “PCP prophylaxis” were strong protecting factors for all-cause mortality, ARM, and NARM. Accordingly, “response to treatment” declined the all-cause mortality by 95% \( (HR = 0.05; p < 0.001) \). Actually, based on the “response to treatment”, ARM and NARM hazards were reduced by 91% \( (SHR = 0.09; p < 0.001) \) and 86% \( (SHR = 0.14; p < 0.001) \), respectively. Similarly, “PCP prophylaxis” reduced all-cause mortality by 57% \( (HR = 0.43; p < 0.001) \), ARM by 67% \( (SHR = 0.33; p < 0.001) \), and NARM by 36% \( (SHR = 0.64; p = 0.021) \). Also, “Last clinical stage” was significantly associated with both ARM and NARD; however, it has no relationship with all-cause mortality. In addition, “stages 3 and 4” were associated with a higher risk of ARM \( (SHR = 7.4; p = 0.025) \) and a lower risk of NARM \( (SHR = 0.24; p < 0.001) \). Late HIV diagnosis, age, and CD4 count at diagnosis were identified as significant risk factors for ARM and all-cause mortality, but not for NARM. Each unit increase in baseline CD4 count declined all-cause mortality by 0.1% \( (HR = 0.999; p < 0.001) \) and ARM by 0.2% \( (SHR = 0.998; p < 0.001) \). Additionally, 1 year increase in age of diagnosis, caused a 4% increase in all-cause mortality \( (HR = 1.04; p < 0.001) \) and a 2% increase in ARM risk \( (SHR = 1.02; p < 0.001) \). Moreover, “late HIV diagnosis” was the most effective risk factor because it increased all-cause mortality and ARM risk by four and about three folds, respectively \( (HR = 4.05; p < 0.001) \) \( (SHR = 2.84; p < 0.001) \). Furthermore, incarceration history increased the all-cause mortality by about 70% \( (HR = 1.69; p = 0.005) \), and the risk of NARM by two folds \( (SHR = 2.14; p = 0.007) \). Finally, gender \( (SHR = 3.57; p = 0.027) \) was a significant risk factor only for NARM (Table 4).

**Discussion**

The results of this study demonstrated that not only ARM is still a major cause of death, but also NARM

---

**Table 1** Characteristics of individuals living with HIV at diagnosis and follow up (total \( N = 1160 \)) (Continued)

| Baseline Characteristics          | Entire cohort | AIDS-related mortality | Non-AIDS-related mortality | All-cause mortality |
|-----------------------------------|---------------|------------------------|----------------------------|---------------------|
| No                                | 629 (54.2)    | 136 (21.6)             | 96 (15.3)                  | 232 (36.9)          |
| Yes                               | 531 (45.8)    | 115 (21.7)             | 44 (8.3)                   | 159 (29.9)          |
| TB status                         |               |                        |                            |                     |
| Negative                          | 1048 (90.3)   | 205 (19.6)             | 123 (11.7)                 | 328 (31.3)          |
| Positive                          | 112 (9.7)     | 46 (41.0)              | 17 (15.2)                  | 63 (56.3)           |
| PCP prophylaxis                   |               |                        |                            |                     |
| No                                | 480 (41.4)    | 108 (22.5)             | 77 (16.0)                  | 185 (38.5)          |
| Yes                               | 680 (58.6)    | 143 (21)               | 63 (9.3)                   | 206 (30.3)          |
| HCV positive co-infection         |               |                        |                            |                     |
| Negative                          | 500 (43.1)    | 116 (23.2)             | 33 (6.6)                   | 149 (29.8)          |
| Positive                          | 660 (56.9)    | 135 (20.5)             | 107 (16.2)                 | 242 (36.7)          |
| HBV positive co-infection         |               |                        |                            |                     |
| Negative                          | 1078 (92.9)   | 231 (21.4)             | 127 (11.8)                 | 358 (33.2)          |
| Positive                          | 82 (7.1)      | 20 (24.4)              | 13 (15.9)                  | 33 (40.2)           |
| Last clinical stage               |               |                        |                            |                     |
| 1, 2                              | 832 (71.7)    | 24 (2.9)               | 91 (10.9)                  | 115 (13.8)          |
| 3, 4                              | 328 (28.3)    | 227 (69.2)             | 49 (14.9)                  | 276 (84.1)          |

* Data are presented as N (%)  
* Other modes of transmission included: who infected HIV with unknown cause, blood transition or through dentistry  
* Include those showing an improvement in clinical factors or increased CD4 counts 6 months after HAART treatment based on medical records and physicians’ comments

---

**Table 2** Death category of individuals living with HIV

| Non-AIDS-Related Death (NARD) | AIDS-Related Death (ARD) |
|-------------------------------|--------------------------|
| Cancer | Other diseases | CVD | Hepatic/liver-related | External death | Other diseases | Cancer | Opportunistic |
| 6 (4%) | 10 (8%) | 12 (9%) | 34 (24%) | 78 (55%) | 2 (1%) | 8 (3%) | 241 (96%) |

*External death: Sudden death, including accident, overdose, and suicide  
*Other diseases: Unknown death categorized based on CD4 count within 6 months prior to the date of death. The CD4 cell count of lower than 200 cells/mm² was categorized as ARM and otherwise as NARM  
*Cancer: Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD
poses a threat to PLWH. This is in agreement with other studies, as well [10, 27]. It seems that after ART, no effective policy has been taken to control NARM in HIV patients in Iran. In contrast to other studies, in which non-AIDS-related malignancies at older ages were the main reason for NARM [2, 3, 28], among Iranian HIV patients, sudden death was more common. External death comprised about half of NARMs (n = 77, 55% of NARMs). Accordingly, overdose most frequently caused NARMs. However, most NARMs originated from non-AIDS malignancies, CVD, and liver diseases in developed countries. Indeed, ART has been reported to be more effective in developed countries where HIV patients receiving ART were shown to survive as long as the normal population do. As a result, the mean age in NARMs can be higher than that in ARMs [29, 30]. However, like a study in South Africa [31], the present study findings indicated that most NARM events were related to overdose and addiction, which occurred at the initial stages of HIV infection and lower ages. In this study, the majority of NARMs were from male patients whose route of HIV transmission was drug injection, and also the cause of their death was overdose (n = 56, 71% of external deaths). In fact, drug abuse has reduced the survival of HIV patients through raising NARMs even prior to the AIDS stage. In consistent with that, a recent study showed an association between serum albumin and NARM events and suggested that the association was stronger for smokers [32].
Previous studies indicated a rapidly increasing number of drug users in Iran from 1998 to 2003 [33–35]. This could have led to higher HIV infection and larger number of deaths in the following years. According to the findings of the current study, the mortality rate reached its peak in 2014 (Fig. 2). On the other hand,
Table 4: Forward stepwise Cox and competing risk model on AIDS-related, non-AIDS-related and all-cause mortality among people living with HIV (N=1160)

| Characteristics at diagnosis | AIDS-related mortality | Non-AIDS-related mortality | All-cause mortality |
|-----------------------------|------------------------|---------------------------|-------------------|
|                             | Adjusted SHR (95% CI)  | Adjusted SHR (95% CI)     | Adjusted HR (95% CI) |
| Gender (men vs. women)      | 3.57 (1.16,11)         |                           |                   |
| Increased age               | 1.02 (1.00,1.04)       |                           | 1.04 (1.02,1.05)  |
| Incarceration history       | 2.14 (1.04,4.41)       |                           | 1.69 (1.26,2.26)  |
| Increased CD4 count         | 0.998 (0.997,0.999)    |                           | 0.999 (0.998,0.999) |

Covariates measured at follow-up

|                                | AIDS-related mortality | Non-AIDS-related mortality | All-cause mortality |
|--------------------------------|------------------------|---------------------------|-------------------|
| Responded HAART 6 months after initiation | 0.09 (0.04,0.20)      | 0.14 (0.09,0.23)         | 0.05 (0.04,0.07)  |
| Late HIV diagnosis             | 2.84 (2.12,3.80)       |                           | 4.05 (3.20,5.12)  |
| Receiving PCP prophylaxis      | 0.33 (0.22,0.51)       | 0.64 (0.46,0.89)         | 0.43 (0.35,0.54)  |
| HIV Clinical stage (3,4 vs. 1,2)| 7.40 (3.89,14.07)     | 0.24 (0.15,0.38)         |                   |

Fig. 3: Cumulative incidence function for AIDS-related death and non-AIDS-related death
case finding of HIV infection has become more efficient in the recent years. Consequently, the number of registered HIV patients has increased and medical care is going to be started earlier for HIV patients, along with reducing the death rate. In 2016, the rate of ARM decreased and became almost equal to that of NARM. These findings were consistent with those of other studies conducted in different countries [2, 3, 28].

In the present study, almost 34% of the patients died during the study period, and about two out of every three deaths were related to opportunistic and AIDS-defining infections with a history of addiction. These findings indicated that addiction had a significant effect on the causes of death and survival of HIV patients in south of Iran regions. On the contrary, several studies from other countries have reported other factors as the major causes of death [2, 3, 28]. More recently, Weber et al. disclosed that non-AIDS malignancies, HIV/HCV-co-infection, liver failure, non-AIDS infections, substance use, and suicide were the main causes of NARM in Switzerland [3]. Morlat et al. also indicated that the most frequent NARM events in France were non-viral hepatitis-related and liver-related malignancies, CVD, and non-AIDS-related infections [11].

Based on the current study findings, late HIV diagnosis in older ages, in stages 3 or 4, or with a lower CD4 count could significantly increase the risk of ARM. These results were in line with the findings of other studies [36, 37]. The results regarding NARM indicated that the male patients in earlier stages and those who had a history of incarceration, also had a significantly shorter survival time. These results were not in agreement with those reported from several developed countries [28]. In a study on low-income individuals in Brazil, Albuquerque et al. claimed that tuberculosis, anemia, and CD4 count lower than 200 cell/mm² were the main reasons for NARM [22].

The present study findings demonstrated a significant improvement in detection and treatment of HIV patients. However, the 90–90-90 targets have not been fulfilled in Iran [21]. In 2010, Prasada et al. predicted that control of HIV epidemics might be unsuccessful in Asia. Therefore, there is a prompt need determining sustainable prevention and treatment strategies and concentrating on programs that are highly effective in preventing the disease, as well as decreasing the number of new HIV infections [38].

The strengths of the present study were using a relatively large sample and making use of competing risks model for performing statistical analysis of the data. However, limitation of this investigation were incomplete medical files, especially about viral load check before 2011. Another study limitation was the restricted access to the patients’ information, especially for the decreased ones. Another important limitation of this study was that, like several other diseases [39, 40], the detection rate of HIV/AIDS is not conveniently high in Iran due to such reasons as the stigmatized attitude of the population and the healthcare personnel [41, 42]. Moreover, we were not able to include one of the HIV exposure categories, MSM (i.e., men who have sex with men) due to its unavailability and that such data are not usually collected in the routine surveillance system in Iran. However, this might not be an issue as the two routes of injection drug use and heterosexual contacts have been considered as the main HIV transmission routes in Iran.

Conclusion

The results of the present study indicated that both ARM and NARM are substantially high among people with HIV in Iran. Applying effective strategies is needed to achieve on time diagnosis of individuals with HIV and provide them with HIV care and treatment services to enhance the survival of the patients. Moreover, males living with HIV require more attention when receiving HIV care and treatment as they experience a higher risk of NARM. In line with the available evidence, the findings of the current research revealed that early HIV care and treatment could substantially reduce ARM and NARM among HIV patients. Therefore, to reduce mortality rate among people with HIV, the current strategies should be revised to improve the timing of treatment initiation and also to optimize the adherence to the treatment.

Abbreviations

AIDS: Acquired Immune Deficiency Syndrome; ARD: AIDS-Related Death; HIV: Human Immunodeficiency Virus; NARD: Non-AIDS-Related Death; PLWH: People Living With HIV; SHR: Sub-distribution Hazard Ratio

Acknowledgments

This article was extracted from a thesis written by Zahra Gheibi for the degree of Master of Science at Shiraz University of Medical Sciences. The authors would like to thank the members of Shiraz HIV research center and faculty members, especially Mr. Mostafa Dianati Nasab, for their great directions. They would also like to thank Dr. Ali Reza Hasan Abadi and Mrs. Nouzarian for their cooperation in data collection. The authors also wish to thank Mr. H. Argasi at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for editing this manuscript. Thanks also go to Ms. A. Kelavanhekoush at the Research Improvement Center of Shiraz University of Medical Sciences for improving the use of English in the manuscript.

Authors’ contributions

ZSH and ZG contributed to the study conception, implementation of the study, design, interpretation and critical was involved in drafting of the manuscript. ZG contributed to collection of data and data analysis. HJ was involved in drafting and revising the manuscript, MF interpretation of data and was involved in drafting and revising the manuscript. SHB contributed to collection of data interpretation of data and was involved in revising the manuscript and MSH contributed to the conception and design of data and revising the manuscript. All authors have read and approved the manuscript, and ensure that this is the case.
Funding
This work was financially supported by Shiraz University of Medical Sciences (grant No. 13946). The funding source had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The data that support the findings of the present study are available from the Iran’s Ministry of Health (MoH) and are not publicly available. The anonymized dataset used for the present research is however available from the corresponding author on reasonable request and with permission of both Ministry of Health and Shiraz HIV/AIDS Research Center.

Ethics approval and consent to participate
This study was conducted according to the principles expressed in the Shiraz HIV center and approved by the local ethics committee of Shiraz University of Medical Sciences by the code IR.SUMS.REC.1396.5198. Based on the approval of Ethics Committee, all informations were collected only by patient's code and their identity was not disclosed. Patient's information was in private.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 2Trauma Research Center, Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 3Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. 4Department of Epidemiology, School of Health & Nutrition, Shiraz University of Medical Sciences, Shiraz, Iran. 5HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran. 6HIV/STI Surveillance Research Center and WHO Collaborating Center for HIV Surveillance Institute for Future Studies in Health, Kerman Sciences, Shiraz, Iran. 7Division of Social and Behavioral Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Received: 10 August 2019 Accepted: 29 November 2019
Published online: 30 December 2019

References
1. WHO. Global Health Observatory (GHO) data. https://www.who.int/gho/hiv/en/ [accessed by Jun 15, 2019].
2. Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8(4):e69–68.
3. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort study. HIV Medicine. 2013;14(4):195–207.
4. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335–43.
5. May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex Health. 2011;8(6):526–33.
6. Jose S, Assessing outcomes of people living with HIV in the UK in relation to the continuum of care framework. UCL (University College London): Thesis; 2018. http://discovery.ucl.ac.uk/10043150/7/Jose_thesis_copyrightremoved.pdf
7. Galli L, Spagnuolo V, Salpietro S, Gianotti N, Cossarini F, Lazzarin A, Castagna A, et al. Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy. Antivir Ther. 2012;17(3):447–58.
8. Aldaz P, Moreno-Iribas C, Esguis N, Iriscar F, Floristan Y, Sola-Boneta J, et al. Mortality by causes in HIV-infected adults: comparison with the general population. BMC Public Health. 2011;11(1):300.
9. Lohse N, Gerstorf J, Kronborg G, Larsen CS, Pedersen G, Nielsen L, et al. Comorbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: a Danish population-based cohort study. JAIDS J Acquir Immune Deficiency Syndr. 2011;57(4):334–9.
10. Collaboration ATC. Causes of death in HIV—infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96.
11. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al.Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28(8):1181–91.
12. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) era. JAIDS J Acquir Immune Deficiency Syndr. 2006;41(2):194–200.
13. UNAIDS data 2019. https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data-en.pdf [accessed by Jun 15, 2019].
14. HIV/AIDS report in Islamic Republic of Iran. https://www.unaids.org/sites/default/files/country/docs/IHRN_2017_countryreport.pdf [accessed by Jun 15, 2019].
15. UNAIDS. Islamic Republic of Iran. http://www.unaids.org/en/regions/countries/iran/ [accessed by Jun 15, 2019].
16. Care and treatment guidelines of HIV/AIDS. http://hivsti.com/wp-content/uploads/2017/04/1.Adult-ART-final-96.pdf [accessed by Oct 1, 2019].
17. Kaplan-Lewis E, Abega JA, Lee M. Aging with HIV in the ART era. Semin Diag Pathol. 2017;34(6):384–97.
18. Alizadeh A, Morasae EK, Almasi-Hashiani A. Methodological and statistical issues related to analysis of survival. Lancet HIV. 2017;4(6):e330.
19. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. JAIDS J Acquir Immune Deficiency Syndr. 2009;50(2):148–52.
20. UNAIDS. 90–90–90: An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/en/resources/documents/90-90-90 [accessed by Jun 15, 2019].
21. Joulai H, Shoshtarian S, Dianatnasab M. Is UNAIDS 90-90-90 target a dream or a reality for Middle East and North Africa region on ending the AIDS epidemic? Rev Study AIDS reviews. 2018;20(1):83–94.
22. Albuquerque MF, Alves DN, Bresani Salvi CC, Batista JD, Ximenes RA, Miranda-Filho DB, et al. Predictors of immunodeficiency-related death in a cohort of low-income people living with HIV: a competing risks survival analysis. Epidemiol Infect. 2017;145(5):914–94.
23. Marin B, Thibault R, Bucher HC, Rondone V, Costagliola D, Dorrucchi M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (London, England). 2009;23(13):1743.
24. Kowaliska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The coding causes of death in HIV (CoDe) project: initial results and evaluation of methodology. Epidemiology. 2011;22(4):516–23.
25. Kuk D, Varadhan R. Model selection in competing risks regression. Stat Med. 2013;32(18):3077–88.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
27. Hernandez V, Sobrino-Vegas P, Burriel MC, Berenguer J, Navarro G, Santos I, et al. Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. AIDS. 2012;26(14):1829–34.
28. Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L, Nunes EP, et al. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. JAIDS J Acquir Immune Deficiency Syndr. 2009;51(6):320–30.
29. Lodri S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, et al. Effect of immediate initiation of Antiretroviral treatment in HIV-positive individuals aged 50 years or older. JAIDS J Acquir Immune Deficiency Syndr. 2017;76(3):311–8.
30. Hart BB, Nordell AD, Okulicz JF, Palfreeman A, Horban A, Kedem E, et al. Inflammation-related morbidity and mortality among HIV-positive adults: how extensive is it? JAIDS J Acquir Immune Deficiency Syndr. 2018;77(1):1–9.
31. Basset IV, Xu A, Giddy J, Bogart LM, Bouille A, Millham L, et al. Assessing rates and contextual predictors of 5-year mortality among HIV-infected and HIV-uninfected individuals following HIV testing in Durban, South Africa. BMC Infect Dis. 2019;19(1):751.
32. Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, et al. Associations between serum albumin and serious non-AIDS events among people living with HIV. AIDS. 2018;32(13):1837–48.

33. Mokri A. Brief overview of the status of drug abuse in Iran. Archives of Iranian Med. 2002;5(3):184–90.

34. Naserbakht M, Tayefi B, Gholami M, Ardabili ME, Shariat SV, Hajebi A, et al. National and sub-rational prevalence, trend, and burden of mental disorders and substance abuse in Iran. 1990-2013, study protocol. Archives of Iranian Med. 2014;17(3):1029–2977.

35. Rahimi-Movaghar A, Amin-Esmaeili M, Haghdoot AA, Sadeghirad B, Mohraz M. HIV prevalence amongst injecting drug users in Iran: a systematic review of studies conducted during the decade 1998-2007. Int J Drug Policy. 2012;23(4):271–8.

36. Geldmacher C, Ngwenyama N, Schuetz A, Petnovas C, Reither K, Heeregrave EJ, et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med. 2010;207(13):2869–81.

37. Bartlett AW, Truong KH, Songtaweesin WN, Chokephaibulkit K, Hansudewechakul R, Ly PS, et al. Characteristics, mortality and outcomes at transition for adolescents with perinatal HIV infection in Asia. Aids. 2018;32(12):1689–97.

38. Rao PJ, Mboi N, Phoolcharoen W, Sarkar S, Carael M. AIDS in Asia amid competing priorities: a review of national responses to HIV. Aids. 2010;24:541–58.

39. Fararouei M, Marzban M, Shahraki G. Completeness of cancer registry data in a small Iranian province: a capture–recapture approach. Health Info Manag J. 2017;46(2):96–100.

40. Kazerooni P, Fararouei M, Nejat M, Akbarpoor M, Sedaghat Z. Under-ascertainment, under-reporting and timeliness of Iranian communicable disease surveillance system for zoonotic diseases. Public Health. 2018;154:130–5.

41. Zarei N, Joulaei H, Darabi E, Fararouei M. Stigmatized attitude of healthcare providers: a barrier for delivering health services to HIV positive patients. Int J Comm Based Nurs Midwifery. 2015;3(4):292.

42. Zarei N, Joulaei H, Fararouei M. Perceived stigma and quality of life among women living with HIV/AIDS. Women Health. 2016;4:e34535.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.